Anti-inflammatory and Organ-protective Effects of <i>Kabasura Kudineer</i>, a Siddha Polyherbal Formulation in Lipopolysaccharide (LPS) induced Systemic Inflammatory Response Syndrome (SIRS) in Wistar Albino Rats

Background: Systemic Inflammatory Response Syndrome (SIRS) is a severe inflammatory state triggered by infections or endotoxins, such as lipopolysaccharide (LPS), leading to a cytokine storm, multi-organ dysfunction, and high mortality despite current therapies. Kabasura Kudineer (KSK), a 15-herb Siddha formulation with proven anti-inflammatory and immunomodulatory effects, is traditionally used for febrile illnesses and shows potential as a safer alternative. Aim: The aim was to evaluate the efficacy and safety of KSK in the rat model of SIRS induced by LPS. Methods: 60 Wistar rats were divided into 4 groups (1-Inflammation control, 2-Hydrocortisone and 3-KSK and 4-Normal control) with 18 rats in groups 1-3 and 6 rats in group 4. SIRS was induced in all groups except the normal control using LPS. Groups 2 and 3 were treated with Hydrocortisone and KSK, respectively, 3 days before LPS injection and continued for up to 72 hours post-LPS injection. No treatment was given to rats in groups 1 and 4. The efficacy parameters (body temperature, WBC count, inflammatory mediators and histopathology of vital organs) and safety parameters (haematological and biochemical parameters and mortality in rats) were assessed at 3 time points, 24-, 48- and 72-hours post LPS injection in groups 1-3. Rats in the normal control group were sacrificed just before LPS in the other groups to get the control data. Results: The findings revealed that KSK significantly attenuated the inflammatory response in SIRS by reducing fever, WBC count and inflammatory mediators with a favourable safety profile. In addition, histopathology of the organs revealed the organ-protective effect of KSK against the inflammation-induced organ injury. Conclusion: Hence, KSK could be used as a potential adjunctive treatment in the management of SIRS, which can be taken up for further preclinical investigations and clinical trials to determine its efficacy in sepsis and SIRS. Major Findings: KSK treatment resulted in

View article page

Download PDF